Advertisement
Johnson & Johnson
Subscribe to Johnson & Johnson

The Lead

Johnson & Johnson Reports 2014 First-Quarter Results

April 15, 2014 7:56 am | News | Comments

Johnson & Johnson today announced sales of $18.1 billion for the first quarter of 2014, an increase of 3.5% as compared to the first quarter of 2013. Operational results increased 5.3% and the negative impact of currency was 1.8%.  Domestic sales increased 2.2%.  International sales increased 4.5%, reflecting operational growth of 7.9% and a negative currency impact of 3.4%.

Arkansas to Ask Court to Reconsider Drug Fine

April 3, 2014 6:29 pm | by Andrew Demillo - Associated Press - Associated Press | News | Comments

Arkansas Attorney General Dustin McDaniel said Thursday he plans to ask the state Supreme Court...

Johnson & Johnson to be Official Healthcare Partner of the USO

April 1, 2014 3:26 pm | News | Comments

Johnson & Johnson has entered a multi-year agreement to be the Official Healthcare Partner...

J&J Accepts $4B Carlyle Offer for Diagnostics Unit

March 31, 2014 8:04 am | News | Comments

Johnson & Johnson today announced that it has accepted the binding offer from The Carlyle...

View Sample

FREE Email Newsletter

Women: J&J Trashed Records in Product Injury Suits

March 26, 2014 1:33 pm | by The Associated Press | News | Comments

Lawyers and advocates for women alleging Johnson & Johnson products injured them are urging the U.S. Justice Department to investigate their claims the health care giant deliberately destroyed many documents critical to the lawsuits.   

Arkansas Court Tosses $1.2B Judgment Against J&J

March 20, 2014 10:31 am | by Chuck Bartels - Associated Press - Associated Press | News | Comments

The Arkansas Supreme Court on Thursday overturned a $1.2 billion judgment against Johnson & Johnson in a lawsuit challenging the drugmaker's marketing of the antipsychotic drug Risperdal. The court ruled that the state improperly sued under a law that applies to health care facilities, not pharmaceutical companies.

Price of New Hep C Drug Questioned by Medical Groups

March 11, 2014 11:55 am | by MATTHEW PERRONE, AP Health Writer | News | Comments

An innovative hepatitis C drug that was only recently hailed as a breakthrough treatment is facing skepticism from some health care providers, as they consider whether it is worth the $1,000-a-pill price.             

Advertisement

Reckitt Benckiser Buying J&J's K-Y brand

March 10, 2014 7:28 am | by The Associated Press | News | Comments

The British consumer goods company Reckitt Benckiser is buying K-Y personal lubricants from U.S. health care giant Johnson & Johnson. Terms of the deal were not disclosed Monday by Reckitt Benckiser, which expects to close the acquisition by the middle of the year.

Montana Settles With J&J Subsidiaries for $5.9M

March 6, 2014 5:32 pm | by Matt Volz - Associated Press - Associated Press | News | Comments

Subsidiaries of Johnson & Johnson have agreed to pay $5.9 million to settle a lawsuit with Montana over how an anti-psychotic drug was marketed, state Attorney General Tim Fox said Thursday. The settlement with Janssen Ortho LLC and Janssen Pharmaceuticals closes the latest in a string of...

J&J Employee Killed in Town House Explosion

March 5, 2014 6:31 pm | by Bruce Shipkowski - Associated Press - Associated Press | News | Comments

The contractor working for New Jersey's largest utility at the site of a town house explosion that killed one resident recently had been fined more than $100,000 by safety regulators for problems at two other sites, but the utility said Wednesday it never had any problems with the construction...

Drug Firms Argue Against $1.2B Arkansas Judgment

February 27, 2014 11:34 am | by The Associated Press | News | Comments

A lawyer for two drug companies told the Arkansas Supreme Court that the state improperly relied on federal regulations in a lawsuit that resulted in a $1.2 billion award over the companies' marketing of an antipsychotics drug.     

US Judge Rules for Company in W.Va. Mesh Lawsuit

February 18, 2014 5:14 pm | by The Associated Press | News | Comments

A federal judge has ruled in favor of a manufacturer in a lawsuit brought by a Texas woman who claimed her pelvic pain was caused by implanted surgical mesh. U.S. District Judge Joseph R. Goodwin on Tuesday dismissed Carolyn Lewis' lawsuit against Johnson & Johnson subsidiary Ethicon.

Advertisement

FDA Rejects Wider Use of J&J Xarelto for Third Time

February 14, 2014 11:59 am | News | Comments

The Food and Drug Administration has rejected — for a third time — Johnson & Johnson's application to expand use of the blood thinner Xarelto to reduce dangerous blood clots and related problems in patients with coronary artery disease.

Pelvic Mesh Lawsuit Goes to Trial in West Virginia

February 10, 2014 2:48 pm | News | Comments

A dozen plaintiffs filed the lawsuit in Texas in 2012. It is among about 50,000 cases filed nationwide that were transferred to West Virginia as part of federal multidistrict litigation. U.S. District Judge Joseph R. Goodwin selected the lawsuit and several other "bellwether" cases to serve as representative cases.

Partners in New NIH-Industry Project to Find Meds

February 4, 2014 1:43 pm | by The Associated Press | News | Comments

Ten pharmaceutical companies, seven disease-related foundations, the drug industry's main trade group and two huge federal agencies have joined together in an unusual collaboration to share information and speed up creation and approval of new drugs needed by patients.

Louisiana Court Tosses AG Office's $330M Risperdal Judgment

January 30, 2014 8:30 am | by MICHAEL KUNZELMAN, Associated Press | News | Comments

A divided Louisiana Supreme Court has overturned a $330 million judgment against two pharmaceutical companies that state Attorney General James "Buddy" Caldwell accused of improperly marketing a drug.        

Janssen Announces New Group Targeting Unmet Global Health Needs

January 22, 2014 8:38 am | News | Comments

Janssen, the pharmaceutical companies of Johnson & Johnson, today announced the formation of Janssen Global Public Health (Janssen GPH), an important new group unifying Janssen's commitment to research, develop, and deliver transformational medicines to address the world's greatest unmet public health needs.

Advertisement

Johnson & Johnson Reports 2013 Fourth-Quarter and Full-Year Results

January 21, 2014 7:57 am | News | Comments

Johnson & Johnson today announced sales of $18.4 billion for the fourth quarter of 2013, an increase of 4.5% as compared to the fourth quarter of 2012.                

Fitch: JNJ's Diagnostics Divestiture Makes Strategic Sense

January 17, 2014 8:57 am | News | Comments

A proposed transaction between Johnson & Johnson (JNJ) and The Carlyle Group is viewed as strategically sound, according to Fitch Ratings. Fitch believes the margins and long-term growth opportunities for this business had been lower versus those for the total firm.

FDA Panel Again Rejects Wider Use of J&J's Xarelto

January 16, 2014 4:38 pm | by The Associated Press | News | Comments

A panel of Food and Drug Administration experts again rejected Johnson & Johnson's bid to expand use of its blood thinner Xarelto to reduce dangerous blood clots in a new group of patients, those with acute coronary artery disease. The condition occurs when narrowed blood vessels restrict blood flow to the heart, increasing the risk of heart attack and other potentially deadly problems.

Johnson & Johnson Offered $4.15B for its Ortho-Clinical Diagnostics Business

January 16, 2014 8:15 am | News | Comments

The Carlyle Group has agreed to acquire Johnson & Johnson’s Ortho-Clinical Diagnostics (OCD) business, a global provider of solutions for screening, diagnosing, monitoring and confirming diseases, for $4.15 billion.     

Oral Arguments Set Over J&J Appeal of $1B Fine

January 13, 2014 2:04 pm | News | Comments

The Arkansas Supreme Court has scheduled oral arguments in Johnson & Johnson's request to overturn a verdict and $1.2 billion fine over the marketing of the antipsychotics drug Risperdal.          

J&J Moves Up as Analyst Raises Pharma Estimate

January 8, 2014 8:11 am | News | Comments

Shares of Johnson & Johnson moved higher Tuesday after an RBC Capital Markets analyst upgraded the stock, saying he expects strong sales of the company's newest drugs.             

North Dakota Gets $923K in National Drug Suit

December 18, 2013 5:01 am | by The Associated Press | News | Comments

Johnson & Johnson is paying North Dakota $923,000 as part of a $1.2 billion national settlement over allegations it illegally promoted two of its best-selling antipsychotics drugs. The state Department of Human Services says North Dakota's share of proceeds comes from a settlement announced last month.

EU Fines Pharmaceutical Giants $22M

December 10, 2013 9:56 am | News | Comments

The European Commission has fined pharmaceuticals giants Johnson & Johnson and Novartis a combined $22 million for colluding to delay the entrance of a cheap generic form of a pain killer to the Dutch market.      

FDA Reaches $1.25M Settlement with J&J Unit

December 4, 2013 6:33 pm | by The Associated Press | News | Comments

The Food and Drug Administration said Wednesday that it reached a $1.25 million settlement with a division of Johnson & Johnson over allegations that it knowingly shipped faulty sterilization equipment used by hospitals.    

FDA Clears Johnson & Johnson Hepatitis C Drug

November 22, 2013 8:42 pm | by The Associated Press | News | Comments

Federal regulators on Friday approved a new drug from Johnson & Johnson for use in treating chronic hepatitis C infections. The U.S. Food and Drug Administration said it approved the drug, a protease inhibitor that blocks a protein needed by the virus to replicate.

J&J to Pay $2.5B to Settle Hip Replacement Suits

November 19, 2013 7:01 pm | by JOHN SEEWER - Associated Press - Associated Press | News | Comments

Johnson & Johnson said late Tuesday that it will pay $2.5 billion to settle thousands of lawsuits brought by hip replacement patients who accuse the company of selling faulty implants that led to injuries and additional surgeries.  

Ohio Gets $52.7M Share of Drug Settlement

November 5, 2013 10:57 am | by The Associated Press | News | Comments

Ohio's Medicaid program will receive $52.7 million through a national settlement with a pharmaceutical company. The $2.2 billion settlement announced Monday involves Johnson & Johnson, one of its subsidiaries, the federal government and several states.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading